Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Analyst Firms Making Recommendations1
- Cantor Fitzgerald
- Raymond James
- HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ADMA Biologics
What is the target price for ADMA Biologics (ADMA)?
The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADMA Biologics (ADMA)?
The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.
When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating ADMA Biologics (ADMA) correct?
While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.